Allergan, Inc.to Acquire SkinMedica,
Inc.

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE:AGN) announces that it has entered into a
definitive agreement with SkinMedica, Inc. to acquire the privately held
company’s topical aesthetics skin care business. Under the terms of the
agreement, Allergan will pay SkinMedica $350 million up-front (subject
to certain adjustments) for the business, which includes a variety of
“physician dispensed” non-prescription aesthetic skin care products and
prescription products. Allergan will also pay SkinMedica an additional
$25 million contingent upon the acquired products achieving a specific
level of net sales. The acquisition, which is expected to close later
this year, does not include the SkinMedica Colorescience aesthetic
make-up line. SkinMedica will be spinning out the Colorescience business
in connection with the closing of the acquisition.

“Allergan is widely recognized for our leadership in the facial
aesthetics area”

“Allergan is widely recognized for our leadership in the facial
aesthetics area,” said David E.I. Pyott, Chairman of the Board,
President and Chief Executive Officer, Allergan. “The acquisition of
SkinMedica will nicely complement our existing facial aesthetics
business, which includes products such as BOTOX® Cosmetic, JUVEDERM®,
and LATISSE®, and will enable us to take a leadership position in the
growing 'physician dispensed' topical aesthetics skin care category.
Most importantly, the acquisition will allow us to expand our product
portfolio to better meet the needs of our existing base of physician
customers and their patients.”

Following the acquisition, Allergan plans to operate SkinMedica as a
separate global business and will leverage a number of Allergan’s
existing preferred customer programs with the SkinMedica product line to
provide additional benefits to physicians and patients. Bob Rhatigan,
who currently serves as Senior Vice President, Facial Aesthetics,
Allergan, will assume the role of Senior Vice President, General Manager
and Chief Executive, SkinMedica. Mary Fisher, Chief Executive Officer,
SkinMedica, will join Allergan and assist Mr. Rhatigan in the
acquisition integration to ensure the maximization of revenue building
opportunities. The Allergan topical aesthetics sales force and the
SkinMedica sales force will continue to represent their respective
product lines over the near term. Following the completion of the
acquisition, a larger and combined SkinMedica sales force will assume
responsibility for the line of products including the revolutionary
SkinMedica TNS product line, Allergan’s VIVITÉ® product line and
LATISSE®, the one and only FDA approved product to treat inadequate or
not enough eye lashes.

About SkinMedica

SkinMedica, Inc. is focused on developing, acquiring, and
commercializing products that improve the appearance of skin. SkinMedica
markets and sells to physicians, with a focus on aesthetics, both
prescription and non-prescription skin care products. The company's full
line of aesthetic skin care products includes the revolutionary TNS
Essential Serum® and hallmark TNS Recovery Complex®. The formulations in
SkinMedica’s clinical skin care collection enhance skin appearance,
reduce signs of aging, and provide other skin care benefits.
SkinMedica's primary prescription product, VANIQA® (eflornithine
hydrochloride) Cream 13.9%, is the only FDA-approved prescription
product for the reduction of unwanted facial hair in women.

About Allergan, Inc.

Allergan is a multi-specialty health care company established more than
60 years ago with a commitment to uncover the best of science and
develop and deliver innovative and meaningful treatments to help people
reach their life’s potential. Today, we have approximately 10,500 highly
dedicated and talented employees, global marketing and sales
capabilities with a presence in more than 100 countries, a rich and
ever-evolving portfolio of pharmaceuticals, biologics, medical devices
and over-the-counter consumer products, and state-of-the-art resources
in R&D, manufacturing and safety surveillance that help millions of
patients see more clearly, move more freely and express themselves more
fully. From our beginnings as an eye care company to our focus today on
several medical specialties, including eye care, neurosciences, medical
aesthetics, medical dermatology, breast aesthetics, obesity intervention
and urologics, Allergan is proud to celebrate more than 60 years of
medical advances and proud to support the patients and physicians who
rely on our products and the employees and communities in which we live
and work. For more information regarding Allergan, go to: www.allergan.com.

Allergan Forward-Looking Statements

This press release contains "forward-looking statements," including, but
not limited to, the statements by Mr. Pyott and other statements
regarding the transaction, including closing and the timing of closing,
statements regarding the expected benefits of the transaction and other
statements regarding how Allergan plans to operate SkinMedica. These
statements are based on current expectations of future events. If
underlying assumptions prove inaccurate or unknown risks or
uncertainties materialize, actual results could vary materially from
Allergan's expectations and projections. Risks and uncertainties
include, among other things, general industry and market conditions;
technological advances and patents attained by competitors; challenges
inherent in the research and development and regulatory processes;
challenges related to product marketing, such as the unpredictability of
market acceptance for new products and/or the acceptance of new
indications for such products; inconsistency of treatment results among
patients; general economic conditions; and governmental laws and
regulations affecting domestic and foreign operations. Allergan
expressly disclaims any intent or obligation to update these
forward-looking statements except as required by law. Additional
information concerning the above referenced risk factors and other risk
factors can be found in Allergan's public periodic filings with the
Securities and Exchange Commission, including the discussion under the
heading "Risk Factors" in Allergan's 2011 Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q. Additional information about
Allergan is available at www.allergan.com
or you can contact the Allergan Investor Relations Department by calling
714-246-4636.